AEON Biopharma (AEON) Balance Sheet: Assets & Liabilities

AEON Biopharma (AEON) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), AEON Biopharma reported total assets of $5.56M and total liabilities of $60.59M. Shareholders' equity was negative at −$55.03M, meaning liabilities exceed assets. Total debt stood at $35.74M against $3.01M in cash and short-term investments, a net debt position of $32.74M.

AEON Biopharma Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for AEON Biopharma, Inc. (AEON) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	3.01	0.01	5.16	9.75	5.13	20.17	6.32
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	105.42
Cash & Short-Term Investments	3.01	0.01	5.16	9.75	5.13	20.17	111.75
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.27
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.39	1.58	1.06	0.09	0.03	0.21	0.13
Total Current Assets	3.40	1.59	6.22	9.84	5.15	20.38	112.15
Non-Current Assets
Property, Plant & Equipment (Net)	1.21	1.52	0.59	0.91	0.92	0.00	0.00
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	1.43
Other Non-Current Assets	0.95	0.03	0.03	0.03	0.36	0.08	0.78
Total Non-Current Assets	2.16	1.55	0.62	0.94	1.28	0.84	2.21
Total Assets	5.56	3.14	6.85	10.78	6.44	0.08	114.35
Current Liabilities
Accounts Payable	0.94	5.91	3.39	7.81	1.19	0.02	1.03
Short-Term Debt	0.25	0.12	0.28	71.12	15.60	0.04	14.79
Current Portion of Long-Term Debt	-	-	-	70.87	15.60	-	-
Accrued Liabilities	2.26	6.48	9.66	8.24	2.94	2.17	-
Other Current Liabilities	5.13	7.55	8.81	3.65	4.01	2.17	1.68
Total Current Liabilities	6.90	14.15	13.05	82.57	20.80	59.59	17.50
Non-Current Liabilities
Long-Term Debt	35.49	12.83	0.00	60.67	70.76	72.16	15.16
Other Non-Current Liabilities	18.20	4.73	146.84	137.95	0.22	10.14	147.57
Total Non-Current Liabilities	53.69	17.56	146.84	198.62	209.46	220.25	162.73
Total Liabilities	60.59	31.71	159.89	281.19	230.26	59.59	180.22
Stockholders' Equity
Common Stock	0.01	0.00	0.00	0.01	0.01	0.00	0.01
Retained Earnings	-470.82	-431.60	-473.60	-474.84	-422.28	-3.59	-333.73
Accumulated Other Comprehensive Income	0.00	0.00	-60.71	0.00	0.00	0.00	0.00
Treasury Stock	-	-	-	0.02	0.02	-	-
Additional Paid-in Capital	415.78	403.02	320.55	187.33	187.35	158.36	266.57
Minority Interest	0.00	0.00	0.00	17.09	11.12	5.04	1.28
Shares Outstanding	12.11	0.56	0.52	0.38	0.38	-	-
Total Stockholders' Equity	-55.03	-28.57	-153.04	-287.50	-234.94	21.41	-67.15
Total Liabilities & Equity	5.56	3.14	6.85	10.78	6.44	21.21	114.35

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AEON Biopharma Balance Sheet

How much debt does AEON Biopharma have?

AEON Biopharma had total debt of $35.74M as of Dec 31, 2025, against $3.01M in cash and short-term investments. Total debt was $12.96M a year earlier.

What are AEON Biopharma's total assets?

AEON Biopharma reported total assets of $5.56M as of Dec 31, 2025, up 77.0% from $3.14M a year earlier. Total liabilities were $60.59M.

What is AEON Biopharma's shareholders' equity?

AEON Biopharma's shareholders' equity was negative at −$55.03M as of Dec 31, 2025, so its liabilities exceeded its assets.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition